Gilead already given 'ample market credit' for remdesivir, says JPMorgan - InvestingChannel

Gilead already given ‘ample market credit’ for remdesivir, says JPMorgan

JPMorgan analyst Cory Kasimov keeps a Neutral rating on Gilead Sciences with an $85 price target after hosting a call with CFO Andy Dickenson and CCO Johanna Mercier. Gilead has already received “ample market credit” for remdesivir, the COVID-19 drug is unlikely to result in tangible long-term cash flows, and a short-term $5B boost to sales has a marginal impact on the company’s overall valuation, Kasimov tells investors in a research note. Further, the analyst thinks Gilead’s other opportunities for growth will take time to play out. Until more evidence of additional growth drivers emerge, Kasimov is “most comfortable” with a Neutral rating on the shares.

Related posts

Carl Icahn Increases His Stake In Take-Two Interactive To 10.68%

ValueWalk

iPad Mini Display Outperformed By Kindle Fire HD & Nexus 7

ValueWalk

Foxconn Might Open Manufacturing Plants In The U.S. [REPORT]

ValueWalk

Peter Cundill Protégé Tim McElvaine on Investing in Japan [VIDEO]

ValueWalk

Set Bing Home Page Image As Lock Screen In Windows 8

ValueWalk

Morning Market News: JCP, APO, MCHP, ZIP, ENR, LGF, EA, ATVI, COV, LNT

ValueWalk